AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dexmedetomidine ๐ถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 835 | 113775-47-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 16 % | |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.09 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 1.60 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 11 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.06 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 20 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK,ULK1 | 44 | |||
| kinase-selectivity-class | AXL,BRAF,CSF1R,DDR1,EPHB4,ERBB2,GRK2,PDK4,PIK3CB,PIK3CD,SIK2 | 11 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 17, 1999 | FDA | HOSPIRA | |
| Jan. 29, 2001 | PMDA | Abbott Japan, Maruishi Pharmaceutical | |
| Sept. 15, 2011 | EMA | Orion Corporation |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bradycardia | 310.88 | 31.01 | 140 | 6227 | 83707 | 90538373 |
| Agitation | 154.53 | 31.01 | 81 | 6286 | 67017 | 90555063 |
| Product administered to patient of inappropriate age | 152.73 | 31.01 | 40 | 6327 | 4613 | 90617467 |
| Anaesthetic complication neurological | 141.89 | 31.01 | 27 | 6340 | 714 | 90621366 |
| Cardiac arrest | 113.77 | 31.01 | 78 | 6289 | 104857 | 90517223 |
| Hypotension | 112.77 | 31.01 | 126 | 6241 | 325271 | 90296809 |
| Phaeochromocytoma crisis | 106.19 | 31.01 | 19 | 6348 | 354 | 90621726 |
| Withdrawal syndrome | 104.04 | 31.01 | 44 | 6323 | 22480 | 90599600 |
| Off label use | 101.92 | 31.01 | 232 | 6135 | 1102020 | 89520060 |
| Sinus arrest | 97.88 | 31.01 | 24 | 6343 | 2122 | 90619958 |
| Myoclonus | 93.73 | 31.01 | 39 | 6328 | 19129 | 90602951 |
| Torsade de pointes | 91.85 | 31.01 | 36 | 6331 | 15146 | 90606934 |
| Respiratory acidosis | 89.52 | 31.01 | 30 | 6337 | 8089 | 90613991 |
| Upper airway obstruction | 86.90 | 31.01 | 19 | 6348 | 1013 | 90621067 |
| Respiratory depression | 84.02 | 31.01 | 34 | 6333 | 15541 | 90606539 |
| Drug interaction | 78.90 | 31.01 | 97 | 6270 | 276356 | 90345724 |
| Glossoptosis | 77.10 | 31.01 | 12 | 6355 | 90 | 90621990 |
| Delirium | 75.80 | 31.01 | 61 | 6306 | 104298 | 90517782 |
| Respiratory failure | 75.14 | 31.01 | 64 | 6303 | 118354 | 90503726 |
| Floppy iris syndrome | 74.95 | 31.01 | 12 | 6355 | 110 | 90621970 |
| Apnoea | 73.87 | 31.01 | 27 | 6340 | 9387 | 90612693 |
| Paradoxical drug reaction | 70.35 | 31.01 | 23 | 6344 | 5743 | 90616337 |
| Drug ineffective for unapproved indication | 68.55 | 31.01 | 48 | 6319 | 66596 | 90555484 |
| Generalised tonic-clonic seizure | 65.96 | 31.01 | 37 | 6330 | 34866 | 90587214 |
| Hyperthermia | 60.72 | 31.01 | 24 | 6343 | 10311 | 90611769 |
| Atrioventricular block second degree | 59.37 | 31.01 | 19 | 6348 | 4433 | 90617647 |
| Sinus bradycardia | 58.51 | 31.01 | 27 | 6340 | 16925 | 90605155 |
| Electrocardiogram QT prolonged | 58.29 | 31.01 | 45 | 6322 | 72411 | 90549669 |
| Drug reaction with eosinophilia and systemic symptoms | 56.50 | 31.01 | 36 | 6331 | 42722 | 90579358 |
| Maternal exposure during delivery | 53.70 | 31.01 | 17 | 6350 | 3829 | 90618251 |
| Sedation complication | 52.35 | 31.01 | 25 | 6342 | 16919 | 90605161 |
| Hypoxia | 51.86 | 31.01 | 42 | 6325 | 72357 | 90549723 |
| Hyperthermia malignant | 51.58 | 31.01 | 13 | 6354 | 1285 | 90620795 |
| Laryngeal stenosis | 51.18 | 31.01 | 13 | 6354 | 1326 | 90620754 |
| Tachyphylaxis | 50.03 | 31.01 | 10 | 6357 | 343 | 90621737 |
| Transcranial electrical motor evoked potential monitoring abnormal | 49.53 | 31.01 | 7 | 6360 | 24 | 90622056 |
| Posterior reversible encephalopathy syndrome | 48.61 | 31.01 | 26 | 6341 | 22313 | 90599767 |
| Product appearance confusion | 46.99 | 31.01 | 8 | 6359 | 110 | 90621970 |
| Hypocapnia | 46.15 | 31.01 | 10 | 6357 | 511 | 90621569 |
| Drug ineffective | 45.29 | 31.01 | 204 | 6163 | 1384094 | 89237986 |
| Stress cardiomyopathy | 45.24 | 31.01 | 21 | 6346 | 13334 | 90608746 |
| Drug withdrawal syndrome | 45.10 | 31.01 | 27 | 6340 | 28696 | 90593384 |
| Hepatic function abnormal | 44.49 | 31.01 | 32 | 6335 | 46256 | 90575824 |
| Product closure removal difficult | 42.82 | 31.01 | 6 | 6361 | 19 | 90622061 |
| Myocardial calcification | 41.32 | 31.01 | 8 | 6359 | 232 | 90621848 |
| Acute respiratory distress syndrome | 40.01 | 31.01 | 25 | 6342 | 28661 | 90593419 |
| Toxicity to various agents | 39.87 | 31.01 | 72 | 6295 | 287774 | 90334306 |
| Tachycardia | 39.62 | 31.01 | 52 | 6315 | 157621 | 90464459 |
| Human herpesvirus 6 infection reactivation | 38.83 | 31.01 | 9 | 6358 | 625 | 90621455 |
| Mental status changes | 38.67 | 31.01 | 29 | 6338 | 44650 | 90577430 |
| Ventricular dysfunction | 38.03 | 31.01 | 13 | 6354 | 3718 | 90618362 |
| Arthralgia | 37.93 | 31.01 | 5 | 6362 | 778517 | 89843563 |
| Arteriospasm coronary | 37.82 | 31.01 | 14 | 6353 | 5036 | 90617044 |
| Anaphylactic shock | 37.78 | 31.01 | 25 | 6342 | 31592 | 90590488 |
| Unwanted awareness during anaesthesia | 37.05 | 31.01 | 8 | 6359 | 402 | 90621678 |
| Abdominal compartment syndrome | 36.94 | 31.01 | 9 | 6358 | 774 | 90621306 |
| Aplastic anaemia | 36.25 | 31.01 | 18 | 6349 | 13251 | 90608829 |
| Serotonin syndrome | 35.96 | 31.01 | 26 | 6341 | 37861 | 90584219 |
| Postoperative delirium | 35.96 | 31.01 | 7 | 6360 | 209 | 90621871 |
| Laryngospasm | 35.49 | 31.01 | 12 | 6355 | 3321 | 90618759 |
| Ventricular fibrillation | 35.28 | 31.01 | 18 | 6349 | 14026 | 90608054 |
| Intensive care unit acquired weakness | 34.66 | 31.01 | 9 | 6358 | 1002 | 90621078 |
| Delayed recovery from anaesthesia | 34.49 | 31.01 | 9 | 6358 | 1021 | 90621059 |
| Device pacing issue | 33.99 | 31.01 | 6 | 6361 | 103 | 90621977 |
| Confusional arousal | 33.46 | 31.01 | 7 | 6360 | 302 | 90621778 |
| Apgar score low | 33.10 | 31.01 | 9 | 6358 | 1194 | 90620886 |
| Echolalia | 32.94 | 31.01 | 7 | 6360 | 326 | 90621754 |
| Accidental overdose | 32.92 | 31.01 | 22 | 6345 | 28251 | 90593829 |
| Fatigue | 31.99 | 31.01 | 21 | 6346 | 1154002 | 89468078 |
| Polyuria | 31.58 | 31.01 | 15 | 6352 | 10025 | 90612055 |
| Local anaesthetic systemic toxicity | 31.06 | 31.01 | 11 | 6356 | 3489 | 90618591 |
| Airway complication of anaesthesia | 31.06 | 31.01 | 7 | 6360 | 429 | 90621651 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bradycardia | 470.86 | 22.53 | 263 | 8457 | 85221 | 42527394 |
| Diabetes insipidus | 389.33 | 22.53 | 100 | 8620 | 3613 | 42609002 |
| Cardiac arrest | 251.36 | 22.53 | 195 | 8525 | 109125 | 42503490 |
| Arteriospasm coronary | 188.70 | 22.53 | 60 | 8660 | 4678 | 42607937 |
| Drug withdrawal syndrome | 147.95 | 22.53 | 77 | 8643 | 21472 | 42591143 |
| Hyperthermia | 147.71 | 22.53 | 65 | 8655 | 12509 | 42600106 |
| Product administered to patient of inappropriate age | 144.09 | 22.53 | 49 | 8671 | 4712 | 42607903 |
| Anaesthetic complication neurological | 134.35 | 22.53 | 31 | 8689 | 705 | 42611910 |
| Intestinal pseudo-obstruction | 130.17 | 22.53 | 38 | 8682 | 2217 | 42610398 |
| Hyperthermia malignant | 115.55 | 22.53 | 36 | 8684 | 2622 | 42609993 |
| Seizure like phenomena | 112.25 | 22.53 | 29 | 8691 | 1068 | 42611547 |
| Delirium | 103.94 | 22.53 | 86 | 8634 | 52433 | 42560182 |
| Hypotension | 98.47 | 22.53 | 183 | 8537 | 257448 | 42355167 |
| Respiratory failure | 84.71 | 22.53 | 117 | 8603 | 128015 | 42484600 |
| Off label use | 84.35 | 22.53 | 303 | 8417 | 638032 | 41974583 |
| Withdrawal syndrome | 79.65 | 22.53 | 45 | 8675 | 14730 | 42597885 |
| Agitation | 74.21 | 22.53 | 78 | 8642 | 64236 | 42548379 |
| Drug ineffective for unapproved indication | 73.91 | 22.53 | 67 | 8653 | 46096 | 42566519 |
| Sedation complication | 72.75 | 22.53 | 26 | 8694 | 2893 | 42609722 |
| Polyuria | 69.31 | 22.53 | 36 | 8684 | 9975 | 42602640 |
| Sinus arrest | 68.41 | 22.53 | 23 | 8697 | 2133 | 42610482 |
| Postoperative ileus | 68.11 | 22.53 | 18 | 8702 | 725 | 42611890 |
| Tachypnoea | 63.83 | 22.53 | 45 | 8675 | 21617 | 42590998 |
| Torsade de pointes | 62.66 | 22.53 | 32 | 8688 | 8562 | 42604053 |
| Tachycardia | 61.84 | 22.53 | 89 | 8631 | 100998 | 42511617 |
| Serotonin syndrome | 56.74 | 22.53 | 45 | 8675 | 25800 | 42586815 |
| Fatigue | 55.47 | 22.53 | 11 | 8709 | 435630 | 42176985 |
| Neuroleptic malignant syndrome | 55.05 | 22.53 | 41 | 8679 | 21431 | 42591184 |
| Acute motor axonal neuropathy | 53.22 | 22.53 | 10 | 8710 | 78 | 42612537 |
| Burkholderia test positive | 48.92 | 22.53 | 15 | 8705 | 1035 | 42611580 |
| Hypocapnia | 47.39 | 22.53 | 12 | 8708 | 407 | 42612208 |
| Upper airway obstruction | 44.14 | 22.53 | 13 | 8707 | 781 | 42611834 |
| Haemodynamic instability | 43.90 | 22.53 | 29 | 8691 | 12528 | 42600087 |
| Electrocardiogram QT prolonged | 42.98 | 22.53 | 51 | 8669 | 47894 | 42564721 |
| Ventricular tachycardia | 42.89 | 22.53 | 41 | 8679 | 30119 | 42582496 |
| Epidermolysis bullosa | 42.53 | 22.53 | 9 | 8711 | 135 | 42612480 |
| Drug interaction | 42.14 | 22.53 | 135 | 8585 | 266864 | 42345751 |
| Myoclonus | 38.06 | 22.53 | 30 | 8690 | 17035 | 42595580 |
| Methaemoglobinaemia | 37.78 | 22.53 | 20 | 8700 | 5754 | 42606861 |
| Laryngomalacia | 34.89 | 22.53 | 9 | 8711 | 329 | 42612286 |
| Hypernatraemia | 34.66 | 22.53 | 23 | 8697 | 10009 | 42602606 |
| Atrioventricular block complete | 34.38 | 22.53 | 24 | 8696 | 11340 | 42601275 |
| Product use issue | 33.59 | 22.53 | 58 | 8662 | 76693 | 42535922 |
| Product use in unapproved indication | 33.47 | 22.53 | 98 | 8622 | 184358 | 42428257 |
| Respiratory depression | 33.38 | 22.53 | 29 | 8691 | 18839 | 42593776 |
| Diarrhoea | 32.55 | 22.53 | 28 | 8692 | 460821 | 42151794 |
| Malignant catatonia | 32.16 | 22.53 | 9 | 8711 | 450 | 42612165 |
| Hyperaesthesia | 31.72 | 22.53 | 18 | 8702 | 5934 | 42606681 |
| Weight decreased | 31.68 | 22.53 | 3 | 8717 | 207945 | 42404670 |
| Hypercapnia | 30.71 | 22.53 | 17 | 8703 | 5344 | 42607271 |
| Floppy iris syndrome | 30.42 | 22.53 | 8 | 8712 | 316 | 42612299 |
| Asthenia | 30.10 | 22.53 | 10 | 8710 | 280783 | 42331832 |
| Hypothermia | 30.08 | 22.53 | 23 | 8697 | 12492 | 42600123 |
| Hypoxia | 29.57 | 22.53 | 52 | 8668 | 69734 | 42542881 |
| Arthralgia | 28.67 | 22.53 | 4 | 8716 | 205234 | 42407381 |
| Stress cardiomyopathy | 28.24 | 22.53 | 13 | 8707 | 2772 | 42609843 |
| Urinary bladder rupture | 27.87 | 22.53 | 6 | 8714 | 98 | 42612517 |
| Delayed recovery from anaesthesia | 27.58 | 22.53 | 10 | 8710 | 1159 | 42611456 |
| Renal ischaemia | 27.54 | 22.53 | 11 | 8709 | 1659 | 42610956 |
| Endotracheal intubation | 27.31 | 22.53 | 14 | 8706 | 3771 | 42608844 |
| Oxygen saturation decreased | 27.15 | 22.53 | 48 | 8672 | 64639 | 42547976 |
| Lung assist device therapy | 26.96 | 22.53 | 5 | 8715 | 36 | 42612579 |
| Cardiac arrest neonatal | 26.96 | 22.53 | 5 | 8715 | 36 | 42612579 |
| Hypotonia | 26.28 | 22.53 | 19 | 8701 | 9480 | 42603135 |
| Phrenic nerve injury | 25.59 | 22.53 | 4 | 8716 | 8 | 42612607 |
| Generalised tonic-clonic seizure | 25.19 | 22.53 | 29 | 8691 | 26350 | 42586265 |
| Death | 25.15 | 22.53 | 36 | 8684 | 471149 | 42141466 |
| Headache | 24.82 | 22.53 | 9 | 8711 | 239360 | 42373255 |
| Dizziness | 24.80 | 22.53 | 10 | 8710 | 249244 | 42363371 |
| Sinus bradycardia | 24.61 | 22.53 | 22 | 8698 | 14831 | 42597784 |
| Transcranial electrical motor evoked potential monitoring abnormal | 24.44 | 22.53 | 4 | 8716 | 12 | 42612603 |
| Abdominal compartment syndrome | 24.39 | 22.53 | 9 | 8711 | 1096 | 42611519 |
| Drug ineffective | 24.30 | 22.53 | 215 | 8505 | 629982 | 41982633 |
| Glossoptosis | 24.25 | 22.53 | 6 | 8714 | 185 | 42612430 |
| Multiple organ dysfunction syndrome | 24.12 | 22.53 | 58 | 8662 | 96977 | 42515638 |
| Blood pressure decreased | 24.11 | 22.53 | 43 | 8677 | 58289 | 42554326 |
| Locked-in syndrome | 24.11 | 22.53 | 7 | 8713 | 400 | 42612215 |
| Porphyria acute | 23.96 | 22.53 | 7 | 8713 | 409 | 42612206 |
| Respiratory alkalosis | 23.95 | 22.53 | 11 | 8709 | 2333 | 42610282 |
| Ileus | 23.45 | 22.53 | 24 | 8696 | 19115 | 42593500 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bradycardia | 668.37 | 25.35 | 345 | 13573 | 155172 | 110420209 |
| Diabetes insipidus | 409.70 | 25.35 | 106 | 13812 | 6464 | 110568917 |
| Cardiac arrest | 371.03 | 25.35 | 257 | 13661 | 196496 | 110378885 |
| Product administered to patient of inappropriate age | 236.30 | 25.35 | 72 | 13846 | 7964 | 110567417 |
| Hyperthermia | 215.31 | 25.35 | 86 | 13832 | 21186 | 110554195 |
| Agitation | 199.51 | 25.35 | 142 | 13776 | 112909 | 110462472 |
| Drug withdrawal syndrome | 196.90 | 25.35 | 96 | 13822 | 37958 | 110537423 |
| Arteriospasm coronary | 194.78 | 25.35 | 64 | 13854 | 9036 | 110566345 |
| Hypotension | 194.00 | 25.35 | 281 | 13637 | 523568 | 110051813 |
| Withdrawal syndrome | 167.86 | 25.35 | 81 | 13837 | 31299 | 110544082 |
| Respiratory failure | 151.84 | 25.35 | 160 | 13758 | 215172 | 110360209 |
| Torsade de pointes | 150.84 | 25.35 | 68 | 13850 | 22532 | 110552849 |
| Hyperthermia malignant | 149.89 | 25.35 | 43 | 13875 | 3857 | 110571524 |
| Delirium | 143.86 | 25.35 | 126 | 13792 | 134899 | 110440482 |
| Sinus arrest | 141.94 | 25.35 | 42 | 13876 | 4200 | 110571181 |
| Intestinal pseudo-obstruction | 137.97 | 25.35 | 39 | 13879 | 3317 | 110572064 |
| Off label use | 135.72 | 25.35 | 454 | 13464 | 1499731 | 109075650 |
| Respiratory depression | 128.37 | 25.35 | 68 | 13850 | 31933 | 110543448 |
| Drug ineffective for unapproved indication | 128.06 | 25.35 | 105 | 13813 | 102733 | 110472648 |
| Drug interaction | 126.79 | 25.35 | 226 | 13692 | 499957 | 110075424 |
| Upper airway obstruction | 111.94 | 25.35 | 29 | 13889 | 1773 | 110573608 |
| Myoclonus | 107.18 | 25.35 | 61 | 13857 | 32937 | 110542444 |
| Electrocardiogram QT prolonged | 104.77 | 25.35 | 96 | 13822 | 108864 | 110466517 |
| Polyuria | 104.66 | 25.35 | 49 | 13869 | 17689 | 110557692 |
| Seizure like phenomena | 103.22 | 25.35 | 29 | 13889 | 2412 | 110572969 |
| Sedation complication | 102.39 | 25.35 | 50 | 13868 | 19805 | 110555576 |
| Postoperative ileus | 102.09 | 25.35 | 25 | 13893 | 1215 | 110574166 |
| Serotonin syndrome | 96.71 | 25.35 | 71 | 13847 | 59082 | 110516299 |
| Respiratory acidosis | 93.52 | 25.35 | 42 | 13876 | 13784 | 110561597 |
| Tachypnoea | 92.18 | 25.35 | 59 | 13859 | 39336 | 110536045 |
| Generalised tonic-clonic seizure | 90.22 | 25.35 | 66 | 13852 | 54614 | 110520767 |
| Phaeochromocytoma crisis | 89.05 | 25.35 | 19 | 13899 | 495 | 110574886 |
| Drug ineffective | 84.88 | 25.35 | 396 | 13522 | 1520144 | 109055237 |
| Tachycardia | 82.68 | 25.35 | 121 | 13797 | 226524 | 110348857 |
| Glossoptosis | 81.65 | 25.35 | 16 | 13902 | 269 | 110575112 |
| Neuroleptic malignant syndrome | 79.66 | 25.35 | 51 | 13867 | 34008 | 110541373 |
| Sinus bradycardia | 78.66 | 25.35 | 48 | 13870 | 29435 | 110545946 |
| Fatigue | 78.04 | 25.35 | 28 | 13890 | 1215930 | 109359451 |
| Atrioventricular block second degree | 75.61 | 25.35 | 31 | 13887 | 8150 | 110567231 |
| Ventricular tachycardia | 74.99 | 25.35 | 57 | 13861 | 49952 | 110525429 |
| Delayed recovery from anaesthesia | 74.40 | 25.35 | 22 | 13896 | 2193 | 110573188 |
| Haemodynamic instability | 73.48 | 25.35 | 42 | 13876 | 22846 | 110552535 |
| Transcranial electrical motor evoked potential monitoring abnormal | 71.59 | 25.35 | 11 | 13907 | 37 | 110575344 |
| Arthralgia | 70.36 | 25.35 | 8 | 13910 | 779624 | 109795757 |
| Hypoxia | 70.20 | 25.35 | 84 | 13834 | 129431 | 110445950 |
| Hypernatraemia | 66.19 | 25.35 | 36 | 13882 | 17797 | 110557584 |
| Stress cardiomyopathy | 64.54 | 25.35 | 34 | 13884 | 15772 | 110559609 |
| Oxygen saturation decreased | 61.89 | 25.35 | 87 | 13831 | 156895 | 110418486 |
| Ventricular fibrillation | 61.74 | 25.35 | 47 | 13871 | 41266 | 110534115 |
| Malaise | 60.33 | 25.35 | 7 | 13911 | 671812 | 109903569 |
| Abdominal compartment syndrome | 59.78 | 25.35 | 18 | 13900 | 1909 | 110573472 |
| Paradoxical drug reaction | 57.54 | 25.35 | 27 | 13891 | 9790 | 110565591 |
| Atrioventricular block complete | 56.94 | 25.35 | 34 | 13884 | 20048 | 110555333 |
| Multiple organ dysfunction syndrome | 53.84 | 25.35 | 80 | 13838 | 151630 | 110423751 |
| Headache | 53.72 | 25.35 | 22 | 13896 | 882355 | 109693026 |
| Diarrhoea | 52.72 | 25.35 | 40 | 13878 | 1139465 | 109435916 |
| Acute motor axonal neuropathy | 52.04 | 25.35 | 10 | 13908 | 151 | 110575230 |
| Nausea | 51.51 | 25.35 | 48 | 13870 | 1235642 | 109339739 |
| Drug reaction with eosinophilia and systemic symptoms | 49.05 | 25.35 | 56 | 13862 | 82039 | 110493342 |
| Mental status changes | 49.03 | 25.35 | 54 | 13864 | 76068 | 110499313 |
| Apnoea | 46.40 | 25.35 | 26 | 13892 | 13613 | 110561768 |
| Asthenia | 45.58 | 25.35 | 15 | 13903 | 688984 | 109886397 |
| Decreased appetite | 45.18 | 25.35 | 4 | 13914 | 475842 | 110099539 |
| Blood pressure decreased | 44.18 | 25.35 | 63 | 13855 | 115028 | 110460353 |
| Product use in unapproved indication | 44.08 | 25.35 | 140 | 13778 | 447237 | 110128144 |
| Pain in extremity | 43.89 | 25.35 | 5 | 13913 | 487113 | 110088268 |
| Postoperative delirium | 43.88 | 25.35 | 12 | 13906 | 903 | 110574478 |
| Laryngeal stenosis | 43.12 | 25.35 | 13 | 13905 | 1385 | 110573996 |
| Posterior reversible encephalopathy syndrome | 43.00 | 25.35 | 35 | 13883 | 33826 | 110541555 |
| Acute respiratory distress syndrome | 41.86 | 25.35 | 42 | 13876 | 53156 | 110522225 |
| Maternal exposure during delivery | 41.64 | 25.35 | 16 | 13902 | 3549 | 110571832 |
| Dizziness | 41.51 | 25.35 | 18 | 13900 | 698175 | 109877206 |
| Pruritus | 41.48 | 25.35 | 11 | 13907 | 581549 | 109993832 |
| Anaphylactic shock | 41.12 | 25.35 | 41 | 13877 | 51505 | 110523876 |
| Hypercapnia | 39.95 | 25.35 | 22 | 13896 | 11137 | 110564244 |
| Cardio-respiratory arrest | 39.54 | 25.35 | 60 | 13858 | 115776 | 110459605 |
| Acute respiratory failure | 39.42 | 25.35 | 48 | 13870 | 75212 | 110500169 |
| Methaemoglobinaemia | 38.22 | 25.35 | 20 | 13898 | 9148 | 110566233 |
| Epidermolysis bullosa | 37.93 | 25.35 | 9 | 13909 | 382 | 110574999 |
| Airway complication of anaesthesia | 37.64 | 25.35 | 10 | 13908 | 674 | 110574707 |
| Product closure removal difficult | 37.55 | 25.35 | 5 | 13913 | 3 | 110575378 |
| Laryngospasm | 37.47 | 25.35 | 16 | 13902 | 4652 | 110570729 |
| Hypothermia | 37.27 | 25.35 | 29 | 13889 | 26273 | 110549108 |
| Unresponsive to stimuli | 37.24 | 25.35 | 43 | 13875 | 63747 | 110511634 |
| Myocardial calcification | 35.85 | 25.35 | 8 | 13910 | 258 | 110575123 |
| Septic shock | 35.72 | 25.35 | 68 | 13850 | 157460 | 110417921 |
| Weight decreased | 35.03 | 25.35 | 8 | 13910 | 468049 | 110107332 |
| Shock | 34.48 | 25.35 | 38 | 13880 | 53550 | 110521831 |
| Rebound effect | 34.19 | 25.35 | 22 | 13896 | 14784 | 110560597 |
| Burkholderia test positive | 33.76 | 25.35 | 9 | 13909 | 615 | 110574766 |
| Hypotonia | 32.95 | 25.35 | 22 | 13896 | 15723 | 110559658 |
| Back pain | 32.93 | 25.35 | 4 | 13914 | 370992 | 110204389 |
| Confusional arousal | 32.78 | 25.35 | 7 | 13911 | 183 | 110575198 |
| Aplastic anaemia | 32.72 | 25.35 | 26 | 13892 | 24282 | 110551099 |
| Malignant catatonia | 32.65 | 25.35 | 9 | 13909 | 697 | 110574684 |
| Hyperpyrexia | 31.93 | 25.35 | 17 | 13901 | 8052 | 110567329 |
| Hepatic function abnormal | 31.53 | 25.35 | 47 | 13871 | 89248 | 110486133 |
| Respiratory distress | 31.42 | 25.35 | 41 | 13877 | 68833 | 110506548 |
| Aggression | 31.39 | 25.35 | 38 | 13880 | 59172 | 110516209 |
| Ileus | 31.32 | 25.35 | 28 | 13890 | 30701 | 110544680 |
| Hypersensitivity | 30.03 | 25.35 | 7 | 13911 | 403991 | 110171390 |
| Drug hypersensitivity | 29.80 | 25.35 | 10 | 13908 | 454080 | 110121301 |
| Fall | 29.38 | 25.35 | 20 | 13898 | 603462 | 109971919 |
| Renal ischaemia | 29.20 | 25.35 | 11 | 13907 | 2312 | 110573069 |
| Intensive care unit acquired weakness | 29.04 | 25.35 | 11 | 13907 | 2348 | 110573033 |
| Dyspnoea | 28.99 | 25.35 | 60 | 13858 | 1106812 | 109468569 |
| Human herpesvirus 6 infection reactivation | 28.48 | 25.35 | 9 | 13909 | 1120 | 110574261 |
| Swelling | 28.34 | 25.35 | 5 | 13913 | 351036 | 110224345 |
| Pain | 28.32 | 25.35 | 48 | 13870 | 954907 | 109620474 |
| Negative pressure pulmonary oedema | 28.17 | 25.35 | 8 | 13910 | 691 | 110574690 |
| Autonomic nervous system imbalance | 28.14 | 25.35 | 14 | 13904 | 5766 | 110569615 |
| Device pacing issue | 27.98 | 25.35 | 6 | 13912 | 160 | 110575221 |
| Overdose | 27.55 | 25.35 | 78 | 13840 | 233716 | 110341665 |
| Phrenic nerve injury | 27.53 | 25.35 | 4 | 13914 | 8 | 110575373 |
| Hyperaesthesia | 27.09 | 25.35 | 19 | 13899 | 14708 | 110560673 |
| Acute chest syndrome | 26.59 | 25.35 | 10 | 13908 | 2093 | 110573288 |
| Electrocardiogram R on T phenomenon | 25.91 | 25.35 | 4 | 13914 | 14 | 110575367 |
| Hypercapnic coma | 25.84 | 25.35 | 7 | 13911 | 508 | 110574873 |
| Echolalia | 25.37 | 25.35 | 7 | 13911 | 544 | 110574837 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05CM18 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives |
| FDA MoA | N0000009918 | Adrenergic alpha2-Agonists |
| FDA EPC | N0000175554 | Central alpha-2 Adrenergic Agonist |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35569 | ฮฑ-adrenergic agonist |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:35717 | sedative |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:51177 | antitussive |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
| FDA PE | N0000175975 | General Anesthesia |
| MeSH PA | D000316 | Adrenergic alpha-Agonists |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D006993 | Hypnotics and Sedatives |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D058647 | Adrenergic alpha-2 Receptor Agonists |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
Related Drugs by ATC class:
N05CM Other hypnotics and sedatives 13 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Conscious sedation | indication | 314271007 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Hypovolemia | contraindication | 28560003 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cardiac Decompensation | contraindication |
๐ถ Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Preanesthesia to general anesthesia | Indication |
| Cats | Sedation and analgesia | Indication |
| Dogs | Preanesthesia to general anesthesia | Indication |
| Dogs | Sedation and analgesia | Indication |
| Dogs | Noise aversion | Indication |
๐ถ Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Dexdomitor | Orion Corp. | 1 |
| SILEO | Orion Corp. | 1 |
| Dexmedesed | Dechra Veterinary Products LLC | 1 |
| Dexmedetomidine Hydrochloride Injection | Akorn Animal Health Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.36 | acidic |
| pKa2 | 6.76 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | PRECEDEX | HOSPIRA | N021038 | March 13, 2013 | RX | INJECTABLE | INJECTION | 8455527 | Jan. 4, 2032 | USE FOR SEDATION |
| EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | PRECEDEX | HOSPIRA | N021038 | March 13, 2013 | RX | INJECTABLE | INJECTION | 8455527 | Jan. 4, 2032 | USE FOR SEDATION |
| EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | PRECEDEX | HOSPIRA | N021038 | Nov. 14, 2014 | RX | INJECTABLE | INJECTION | 8455527 | Jan. 4, 2032 | USE FOR SEDATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11786508 | Dec. 29, 2037 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11839604 | Dec. 29, 2037 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11786508 | Dec. 29, 2037 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11839604 | Dec. 29, 2037 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 10792246 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11497711 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11517524 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 10792246 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11497711 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11517524 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11890272 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11890272 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11998529 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12109196 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11890272 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11890272 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11998529 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12109196 | July 17, 2040 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11806334 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11998528 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12090140 | Jan. 12, 2043 | A METHOD OF TREATING AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12138247 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12364683 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11806334 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 11998528 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12090140 | Jan. 12, 2043 | A METHOD OF TREATING AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12138247 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 12364683 | Jan. 12, 2043 | ACUTE TREATMENT OF AGITATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | Nov. 19, 2028 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | Nov. 19, 2028 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-2B adrenergic receptor | GPCR | AGONIST | Ki | 9.70 | IUPHAR | CHEMBL | |||
| Alpha-2C adrenergic receptor | GPCR | AGONIST | Ki | 9.30 | IUPHAR | CHEMBL | |||
| Alpha-2A adrenergic receptor | GPCR | AGONIST | EC50 | 8.82 | CHEMBL | CHEMBL | |||
| Alpha-1A adrenergic receptor | GPCR | Ki | 6.70 | PDSP | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 10.82 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.50 | PDSP | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.49 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 6.04 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 10.82 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | EC50 | 6.42 | CHEMBL | |||||
| Adrenergic receptor alpha-2 | GPCR | Ki | 10.82 | CHEMBL | |||||
| Adrenergic receptor alpha-1 | GPCR | Ki | 8.30 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | EC50 | 6.44 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021214 | VUID |
| N0000148660 | NUI |
| D00514 | KEGG_DRUG |
| 145108-58-3 | SECONDARY_CAS_RN |
| 228054 | RXNORM |
| 4021214 | VANDF |
| 4021215 | VANDF |
| C0113293 | UMLSCUI |
| CHEBI:4466 | CHEBI |
| CZX | PDB_CHEM_ID |
| CHEMBL778 | ChEMBL_ID |
| DB00633 | DRUGBANK_ID |
| CHEMBL2106195 | ChEMBL_ID |
| D020927 | MESH_DESCRIPTOR_UI |
| 5311068 | PUBCHEM_CID |
| 521 | IUPHAR_LIGAND_ID |
| 6277 | INN_ID |
| 67VB76HONO | UNII |
| 227894 | MMSL |
| 29394 | MMSL |
| 31641 | MMSL |
| 8598 | MMSL |
| d04505 | MMSL |
| 008084 | NDDF |
| 008085 | NDDF |
| 116348007 | SNOMEDCT_US |
| 437750002 | SNOMEDCT_US |
| 438079000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9198 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 30 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9525 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 30 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9526 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 30 sections |
| Dexmedetomidine HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9532 | INJECTION | 100 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-9555 | INJECTION | 200 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-9557 | INJECTION | 400 ug | INTRAVENOUS | ANDA | 29 sections |
| PRECEDEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9938 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | NDA | 18 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0155 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 31 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1174 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1434 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1454 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1596 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1638 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1660 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2815 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3301 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-4596 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 31 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7838 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7853 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7875 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3493 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3494 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3495 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |
| Dexmedetomidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-239 | INJECTION, SOLUTION | 100 ug | INTRAVENOUS | ANDA | 27 sections |
| DEXMEDETOMIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-432 | INJECTION, SOLUTION | 100 ug | INTRAVENOUS | ANDA | 28 sections |
| Dexmedetomidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-055 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | ANDA | 32 sections |
| Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-615 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 32 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-617 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 33 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 36000-262 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | ANDA | 28 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-146 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | ANDA | 31 sections |